GTBPHealthcare · BiotechnologyThe 1 Wall Street analysts covering GT Biopharma, Inc. hold a median 12-month price target of $3 — +949.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores GT Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GTBP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +949.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Dec 2024 | Roth MKM | Initiates | Buy | $11 |
| 8 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 7 Aug 2023 | EF Hutton | Reiterates | Hold | $2.00 |
| 5 June 2023 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 17 May 2023 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 16 May 2023 | EF Hutton | Reiterates | Hold | $2.00 |
| 3 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 31 Mar 2023 | EF Hutton | Reiterates | Hold | $2.00 |
| 5 Jan 2023 | EF Hutton | Initiates | Hold | $2.00 |
| 13 Sept 2022 | HC Wainwright & Co. | Maintains | Buy | $25 → $5.00 |
| 24 May 2021 | HC Wainwright & Co. | Initiates | Buy | $25 |
| 13 Apr 2021 | B. Riley FBR | Initiates | Buy | — |
| 13 Apr 2021 | B. Riley Securities | Initiates | Buy | — |
| 17 Mar 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GTBP appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 30% of US stocks
Cheaper than 85% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GT Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
GT Biopharma reported its second quarter 2026 financial results. The Phase 1 trial of GTB-3650 TriKE remains ongoing, with an update anticipated in the second half of 2026.
Why it matters — The update indicates progress in the ongoing Phase 1 trial of GTB-3650, a key pipeline candidate for GTBP watchers to follow.
The 1 Wall Street analysts covering GT Biopharma, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering GT Biopharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GT Biopharma, Inc. 14 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, GT Biopharma, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +949.0% from the last close, and Ticker Nerd's factor model ranks GT Biopharma, Inc. 14 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering GT Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GTBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.
GT Biopharma, Inc. returned -73.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapeutics.
The most recent item we track (GlobeNewsWire, 14 Aug 2026): "GT Biopharma Reports Second Quarter 2026 Financial Results". GT Biopharma reported its second quarter 2026 financial results. The Phase 1 trial of GTB-3650 TriKE remains ongoing, with an update anticipated in the second half of 2026.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapeutics. It leverages proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms to enhance natural killer (NK) cell functions against cancer. Key product candidates include GTB-3650, targeting CD33 on myeloid leukemias in Phase 1 clinical trials; GTB-5550, directed at B7-H3 on advanced solid tumors; and GTB-7550, aimed at lupus and other autoimmune disorders. These therapies address unmet needs in hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as solid tumors and autoimmune conditions. GT Biopharma, Inc. holds a worldwide license from the University of Minnesota for TriKE technology commercialization. Headquartered in San Francisco, California, the company plays a role in advancing NK cell engager therapies within the immuno-oncology market.
CEO Mr. Michael Martin Breen L.L.B. · 1 employees · United States · https://www.gtbiopharma.com